Pfizer second shot associated with heart damage in teen study reveals : The Canadian Business Daily

Health 2786 Views Edited by John Stokes

Pfizer second shot associated with heart damage in teen study reveals

According to a new peer-reviewed study, more than two-thirds of adolescents with COVID-19 vaccine-related myopericarditis had persistent heart abnormalities months after their initial diagnosis, raising concerns about long-term effects and contradicting health officials' claims that the condition is "mild."

More than two-thirds of adolescents with COVID-19 vaccine-related myopericarditis had persistent heart abnormalities months after their initial diagnosis, raising concerns about long-term effects documents this study.

The findings, published March 25 in the Journal of Pediatrics, call into question the claims of U.S. health agencies, including the Centers for Disease Control and Prevention (CDC), that heart inflammation associated with Pfizer and Moderna mRNA vaccines is "mild."

Seattle Children's Hospital researchers examined cases of patients under the age of 18 who presented to the hospital with chest pain and an elevated serum troponin level between April 1, 2021, and January 7, 2022, within one week of receiving a second dose of Pfizer's vaccine.

While 35 patients met the criteria, 19 were ruled out for a variety of reasons.

The remaining 16 patients had cardiac magnetic resonance imaging (MRI) three to eight months after their initial examination.

The MRIs revealed that 11 patients had persistent late gadolinium enhancement (LGE), albeit at lower levels than in previous months.

"The presence of LGE is an indicator of cardiac injury and fibrosis and has been strongly associated with a worse prognosis in patients with classical acute myocarditis," according to the study.

LGE was found to be a predictor of all-cause death, cardiovascular death, cardiac transplant, rehospitalization, recurrent acute myocarditis, and the need for mechanical circulatory support in a meta-analysis of eight studies.